翰森创新药收入占比超八成 中国头部药企加速全球化创新突围

21世纪经济报道
Aug 21, 2025

一张中期业绩公告背后,中国头部药企的创新转型与国际化战略路径清晰可见。  8月18日,翰森制药(03692.HK)发布2025年中期业绩公告。2025年上半年,翰森制药收入约人民币74.34亿元,同比增长约14.3%;溢利约31.35亿元,同比增长约15.0%;每股基本盈利约0.53元,同比增长约14.8%。  2025年上半年,翰森制药创新药与合作产品销售收入约61.45亿元,同比增长22.1%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10